88 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
in the OLE study partially offset by a decrease in clinical costs associated with the Phase 2 nomlabofusp trial discussed above.
General and administrative … offset by a decrease of $0.2 million in legal fees.
For the full year 2023, the Company reported a net loss of $36.9 million, or $0.84 per share
424B5
LRMR
Larimar Therapeutics Inc
14 Feb 24
Prospectus supplement for primary offering
5:08pm
the sale or other taxable disposition of our common stock, which may be offset by U.S. source capital losses of the Non-U.S. Holder (even though
424B5
vni ow0bgk
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
9eatuoz7zjue4
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
n0o48cdu10aiq10sy
10 Aug 23
Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results
7:03am
8-K
EX-99.1
g5yg 7q5p
15 May 23
Results of Operations and Financial Condition
7:05am
8-K
EX-99.1
knom1bf
10 Nov 22
Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results
7:01am
8-K
EX-99.1
9lsyaoy z2
11 Aug 22
Larimar plans to submit a complete response to CTI-1601’s clinical hold in the third quarter of 2022
4:13pm
8-K
EX-99.1
5jh n2p60fwh1y0
12 May 22
Larimar Therapeutics Reports First Quarter 2022 Operating and Financial Results
7:12am
8-K
EX-99.1
z013twdj
25 Mar 22
Larimar Therapeutics Reports Fourth Quarter and Full Year 2021 Operating and Financial Results
7:11am